Roche Acquires Cardion’s IL-15 Antagonist
By Business Review Editor
Pharma Deals Review: Vol 2003 Issue 39 (Table of Contents)
Published: 1 Aug-2003
DOI: 10.3833/pdr.v2003.i39.873 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
Roche entered into an acquisition agreement with Cardion for acquiring rights to Cardion’s interleukin-15 antagonist, CRB-15 for treating rheumatoid arthritis and transplant rejection, thus substantially expanding its product portfolio in the fields of autoimmune diseases and transplantation...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS